CorMedix Clarifies FY27 DefenCath Sales Guidance Upward After Earnings Call Misstatement

summarizeSummary

CorMedix Inc. clarified its full-year 2027 DefenCath sales guidance to $100 million to $140 million, correcting an inadvertent lower figure mentioned during its recent earnings call, and released an updated investor presentation highlighting strong growth prospects.

check_boxKey Events

• FY27 DefenCath Sales Guidance Clarified Upward

  CorMedix reaffirmed its full-year 2027 DefenCath sales guidance to a range of $100 million to $140 million, correcting an inadvertent statement from its March 5 earnings call that cited a lower upper bound of $125 million.

• Updated Investor Presentation Released

  The company furnished an updated investor presentation (Exhibit 99.1) providing a comprehensive overview of its diversified product portfolio, financial highlights, and strategic growth initiatives.

• Key Product Pipeline Updates Highlighted

  The presentation detailed significant growth opportunities, including the REZZAYO prophylaxis indication (Phase 3 data expected Q2 2026 with a >$2B addressable market) and the DefenCath TPN indication (Phase 3 study underway with a ~$500-750MM addressable market).

auto_awesomeAnalysis

CorMedix Inc. filed an 8-K to correct an inadvertent statement made during its March 5, 2026 earnings call, reaffirming its full-year 2027 DefenCath sales guidance in the range of $100 million to $140 million. This clarification is significant as it raises the upper end of the previously misstated guidance ($100 million to $125 million), indicating a more optimistic outlook for a key product. The accompanying investor presentation provides a comprehensive overview of the company's strong financial position, successful DefenCath launch, and substantial growth opportunities, including the REZZAYO prophylaxis and DefenCath TPN indications, reinforcing a positive long-term investment thesis.